Sapiens Steering Brain Stimulation is an emerging medical device company with a mission to bring the innovative concept of Steering Deep Brain Stimulation (DBS) to more patients who can benefit from this advanced treatment of degenerative or functional brain disorders, such as Parkinson’s disease, dystonia and other currently emerging indications.
Sapiens’ ambition is to improve the therapeutic efficacy of DBS, to shorten and simplify the clinical procedure, and to improve patient comfort. Sapiens’ high-resolution, MRI-conditionally safe SureStim-1® implant system enables the reduction of stimulation-induced side-effects by precisely shaping the stimulation field to the intended target area. The SureSuite® products, SurePlan®, SurePlace® and SureTune®, provide an integrated, image-based solution for planning and programming an optimal DBS treatment.
With offices in Eindhoven, the Netherlands and Munich, Germany, Sapiens was founded in 2011. The company is a spin-out of Royal Philips, and is backed by Wellington Partners, Edmond de Rothschild Investment Partners, Life Sciences Partners (LSP), the Wellcome Trust, INKEF Capital and Gilde Healthcare Partners. Additional support is provided by the Michael J Fox Foundation and the European Union Framework Program VII. Sapiens’ Steering Brain Stimulation lead, implant and image-guided programming are all based on patented technologies.